Resistance of hepatitis B virus to antiviral drugs: Current aspects and directions for future investigation

Antiviral Chemistry and Chemotherapy

Volumn 12, Issue 1, 2001, Pages 1-35

  Delaney IV, W E ^a   Locarnini, S ^a   Shaw, T ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

Drug resistance; Hepatitis B virus; Nucleoside analogues

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; BETA LEVO THYMIDINE; CLEVUDINE; DIAMINOPURINE DIOXOLANE; DNA POLYMERASE; ELVUCITABINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; GANCICLOVIR; LAMIVUDINE; LOBUCAVIR; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; COMBINATION CHEMOTHERAPY; CROSS RESISTANCE; DRUG UPTAKE; ENZYME INHIBITION; GENE MUTATION; HEPADNAVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS REPLICATION;

EID: 0034968926     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020101200101     Document Type: Review

References (217)

1. Identifcation and characterization of mutations in hepatitis B virus resistant to lamivudine
2. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamlvudine
3. Mammalian deoxyribonucleoside kinases
4. The processivity of DNA synthesis exhibited by drug-resistant variants of human immunodeficiency virus type-1 reverse transcriptase
5. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation
6. Mutational studies of human immunodeficiency virus type 1 reverse transcriptase: The involvement of residues 183 and 184 in the fidelity of DNA synthesis
7. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy
8. Clinical experience with famciclovir against hepatitis B virus
9. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease
10. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
11. Hepatitis B virus - The major etiology of hepatocellular carcinoma
12. Hepatitis B virus X protein interferes with cellular DNA repair
13. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
14. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine
15. Antiviral strategies in chronic hepatitis B virus infection: I. Establishment of an in vitro system using the duck hepatitis B virus model
16. Prostaglandin E plus famciclovir - A new concept for the treatment of severe hepatitis B after liver transplantation
17. Reconstructing the complex evolutionary history of hepatitis B virus
18. Recombination between sequences of hepatitis B virus from different genotypes
19. Virus dynamics and drug therapy
20. Relationships within and between genotypes of hepatitis B virus at points across the genome: Footprints of recombination in certain isolates
21. Baculovirus-mediated gene transfer into mammalian cells
22. Antiviral L-nucleosides specific for hepatitis B virus infection
23. Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation
24. Nucleoside transporters of mammalian cells
25. Production of hepatitis B virus in vitro by transient expression of cloned HBV DNA in a hepatoma cell line
26. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
27. A novel action of human apurinic/apyrimidinic endonuclease. Excision of L-configuration deoxyribonucleoside analogs from the 3′ termini of DNA
28. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy) ethyl]adenine in vitro
29. In vitro susceptibility of wild type and drug resistant hepatitis B virus to (-)-β-D-2,6 diaminopurine dioxolane (DAPD) and 2′-fluoro-5-methyl-β-L- arabinofuranosyluracil (FMAU)
30. Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds
31. A combinatorial ledge: Reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance
32. The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection
33. In vitro anti-hepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir
34. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically WHC-infected woodchucks
35. In vivo antiviral activity and pharmacoldnetics of (-)-cis-5-fluoro-1-[2(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks
36. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA
37. Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription
38. Molecular modeling and biochemical characterization reveals the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and Emtricitabine (FTC)
39. DNA polymerase activity of hepatitis B virus particles: Differential inhibition by L-enantiomers of nucleotide analogs
40. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss
41. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B
42. Cross-resistance analysis of lamivudine, sdefovir, and entecavir using a cell culture model of HBV replication
43. The recombinant HBV baculovirus as an improved model for the in vitro assesment of antihepadnaviral compounds
44. Cross-resistance testing of antihepadnaviral compounds using novel hepatitis B virus baculoviruses encoding drug-resistant strains of hepatitis B virus
45. Cross-resistance/sensitivity testing of antihepadnavirai compounds using novel HBV baculoviruses encoding drug-resistant strains of HBV
46. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus
47. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2′,3′-dideoxy-3′-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA
48. An attempt to unify the structure of polymerases
49. A preliminary trial of lamivudine for chronic hepatitis B infection
50. Lamivudine as initial treatment for chronic hepatitis B in the United States
51. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals
52. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus
53. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2′,3′-dideoxy-3′-thiacytidine] in vitro
54. The mutation in duck hepatitis B virus polymerase which confers resistance to lamivudine (beta-L-(-)-thlacytidine; -3TC) also confers cross-resistance to beta-L-dideoxy-5-fluorocytidine (FddC)
55. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)
56. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance
57. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus
58. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoslde analogues
59. Hepadnaviridae and their replication
60. Hepatitis B virus reverse transcriptase and its many roles in hepadnaviral genomic replication
61. In vitro analysis of cross-resistance profiles of new antivirals for chronic HBV infection
62. Mutation rate of the hepadnavirus genome
63. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis
64. Viral clearance without destruction of infected cells during acute HBV infection
65. Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G-A hypermutation
66. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure
67. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections
68. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma
69. Long-term mutation rates in the hepatitis B virus genome
70. An aberrant genotype revealed in recombinant hepatitis B virus strains from Vietnam
71. Structure of the RNA-dependent RNA polymerase of poliovirus
72. Enhanced 9-(2-phosphonylmethoxyethyl)-adenine secretion by a specific, indomethacin-sensitive efflux pump in a mutant 9-(2-phosphonylmethoxyethyl)adenine-resistant human erythroleukemia K562 cell line
73. Viral dynamics in vivo: Limitations on estimates of intracellular delay and virus decay
74. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: Two placebo-controlled Phase II studies
75. Efficient gene transfer into human hepatocytes by baculovirus vectors
76. Quantitative assessment of hepatitis B virus DNA during a 24-week course of lamivudine therapy
77. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns
78. Eukaryotic DNA polymerases, a growing family
79. Human cytosolic nucleotidase I: Charaterization and role in nucleoside analog resistance
80. Pharmacodynamics of (-)-beta-2′,3′-dideoxy-3′-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans
81. Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action
82. Hepatitis B virus X protein inhibits nucleotide excision repair
83. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants
84. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial
85. Global programme for control of hepatitis B infection
86. Inhibition of duck hepatitis B virus replication by 2′,3′-dideoxycytidine. A potent inhibitor of reverse transcriptase
87. Valine of the YVDD motif of moloney murine leukemia virus reverse transcriptase: Role in the fidelity of DNA synthesis
88. Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site
89. Treatment of chronic woodchuck hepatitis virus infection in the eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans
90. Mutations in the woodchuck hepatitis B virus (WHV) genome that confer resistance to lamivudine and penciclovir
91. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication
92. A cell culture assay for compounds which inhibit hepatitis B virus replication
93. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study
94. L- and D-enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity
95. Excision of beta-L- and beta-D-nucleotide analogs from DNA by p53 protein
96. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2′-deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA
97. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues
98. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: A novel system for screening potential inhibitors of HBV replication
99. A one-year trial of lamivudine for chronic hepatitis B
100. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial
101. Roles of the three major phosphorylation sites of hepatitis B virus core protein in viral replication
102. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells
103. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infected Chinese: A viral dynamics study
104. In vitro and in vivo comparison of the abilities of purine and pyrimidine 2′,3′-dideoxynucleosides to inhibit duck hepadnavirus
105. Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents
106. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site
107. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
108. Long term therapy with the guanosine nucleoside analogue penciclovir controls chronic duck hepatitis B virus infection in vivo
109. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus
110. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
111. Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance
112. Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV-infected patients
113. Hepatitis B infection: Pathogenesis and management
114. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection
115. Chronic hepatitis B virus infection: Treatment strategies for the next millennium
116. Asymmetric replication of duck hepatitis B virus DNA in liver cells: Free minus-strand DNA
117. Lamivudine therapy of WHV-infected woodchucks
118. The enantioselectivity of enzymes involved in current antiviral therapy using nucleoside analogues: A new strategy?
119. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
120. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism
121. Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity
122. Response to therapy with adefovir dipivoxil is durable for 48 weeks and correlates with baseline HIV reverse transcriptase as well as baseline in vitro susceptibility to adefovir
123. Abasic site recognition by two apurinic/apyrimidinic endonuclease families in DNA base excision repair: The 3′ ends justify the means
124. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus
125. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy
126. Hepatitis B virus X protein: Structure, function and biology
127. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy
128. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B
129. Novel molecular approaches toward therapy of chronic hepatitis B
130. Hepatitis B virus replication: Novel roles for virus-host interactions
131. Hepatitis B virus replication - An update
132. Lamivudine therapy for chronic hepatitis B: A six month randomized dose-ranging study
133. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes
134. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
135. Viral dynamics in hepatitis B virus infection
136. Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus
137. Structure of large fragment of Escherichia coli DNA polymerase I complexed with dTMP
138. In vivo study of the mechanism of action of antiviral agents against hepadnavirus replication in the liver. Resistance of supercoiled viral DNA
139. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
140. Influence of B domain mutation (L528M) of the hepatitis B virus polymerase on replication ability and resistance to nucleoside analogues
141. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
142. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
143. Similarity relations of DNA and RNA polymerases investigated by the principal component analysis of amino acid sequences
144. Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase
145. Analysis of RNA-dependent RNA polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure
146. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays
147. The dynamics of hepatitis B virus infection
148. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: Performance of three commercial assays
149. Antiviral activity of clevudine [L-FMAU (1-(2-fluoro-5-methyl-L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax)
150. Excision of beta-D- and beta-L-nucleotide analogs from DNA by the human cytosolic 3′-to-5′ exonuclease
151. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
152. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin
153. Increase in the frequency of hepadnavirus DNA integrations by oxidative DNA damage and inhibition of DNA repair
154. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance
155. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements
156. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy
157. Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential
158. Human immunodeficiency virus reverse transcriptase. A kinetic analysis of RNA-dependent and DNA-dependent DNA polymerization
159. A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent
160. The woodchuck: An animal model for hepatitis B virus infection in man
161. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
162. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs
163. Hepatitis B virus biology
164. Generation of replication-competent hepatitis B virus nucleocapsids in insect cells
165. Recombinant human hepatitis B virus reverse transcriptase is active in the absence of the nucleocapsid or the viral replication origin, DR1
166. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B
167. Inhibitory activity of new nucleoside analogs on wild type and YMDD mutants of the hepadnavirus reverse transcriptase
168. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA
169. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions
170. Stereoisomers of deoxynucleoside 5′-triphosphates as substrates for template-dependent and -independent DNA polymerases
171. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients
172. Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase
173. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus
174. Combination chemotherapy for hepatitis B virus: The path forward?
175. Combination chemotherapy for hepatitis B virus: The final solution?
176. Hepatic purine and pyrimidine metabolism: Implications for antiviral chemotherapy of viral hepatitis
177. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus
178. Animal models for hepatitis B infections - Duck hepatitis. Chapter 123
179. Selection of hepatitis B surface 'escape' mutants during passive immune prophylaxis following liver transplantation: Potential impact of genetic changes on polymerase protein function
180. A unified DNA- and dNTP-binding mode for DNA polymerases
181. Antiviral guanosine analogs as substrates for deoxyguanosine kinase: Implications for chemotherapy
182. Stereochemical control of DNA biosynthesis
183. DNA polymerases: Structural diversity and common mechanisms
184. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region
185. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy
186. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate
187. Efficacy of lamivudine in patients with hepatitis B e antigen- negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
188. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin
189. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus
190. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation
191. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
192. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
193. Physiological concentrations of purines and pyrimidines
194. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
195. Stable expression and replication of hepatitis B virus genome in an integrated state in a human hepatoma cell line transfected with the cloned viral DNA
196. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells
197. An in vitro system for screening anti-hepatitis B virus drugs
198. Anti-human immunodeficiency virus drug combination strategies
199. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis
200. Novel mechanism for reverse transcription in hepatitis B viruses
201. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum
202. Genotypic and phenotypic analysis of HBV isolated from patients exposed to adefovir dipivoxil for up to 36 weeks
203. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs
204. Mutations in the primer grip region of HIV reverse transcriptase can increase replication fidelity
205. A plethora of lesion-replicating DNA polymerases
206. Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene
207. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
208. Origin and evolution of retroelements based upon their reverse transcriptase sequences
209. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
210. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance
211. Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA
212. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma
213. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir
214. Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: Long-term follow-up
215. Dynamics of hepatitis B virus infection in vivo
216. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine
217. 2′,3′-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo